Biological research on schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 52, Issue SUPPL., 1998, Pages

  Toru, Michio ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Dopamine D2 receptor; Dopamine D2 receptor gene; Glutamate receptors; Kainate receptor; N methyl D aspartate receptor; Schizophrenia; Tyrosine hydroxylase

Indexed keywords

DOPAMINE 2 RECEPTOR; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; TYROSINE 3 MONOOXYGENASE;

BINDING AFFINITY; CLINICAL RESEARCH; CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; DRUG POTENCY; ENZYME ACTIVITY; GENE FREQUENCY; HUMAN; MISSENSE MUTATION; PROTEIN EXPRESSION; RECEPTOR DENSITY; RECEPTOR GENE; SCHIZOPHRENIA;

EID: 0032417728     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.1998.tb03213.x     Document Type: Conference Paper

References (28)

1. Toru M, Kurumaji A, Ishimaru M. Minireview: Excitatory amino acids: Implications for psychiatric disorders research. Life Sci. 1994; 5: 1683-1699.
2. Kim JS, Kornhuber HH, Schmid-Burg KW, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and new hypothesis on schizophrenia. Neurosci. Lett. 1980; 20: 379-382.
3. Perry TL. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci. Lett. 1982; 28: 81-85.
4. Gattaz WF, Gasser T, Beckmann H. Multi dimensional analysis of the concentration of 17 substances in the CSF of schizophrenics and controls. Biol. Psychiatry 1985; 20: 360-366.
5. Korpi ER, Kaufman CA, Marnela K-M. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiat. Res. 1987; 20: 337-345.
6. Toru M, Kurumaji A, Kumashiro S, Suga I, Takashima M, Nishikawa T. Excitatory amino acidergic neurones in chronic schizophrenic brain. Mol. Neuropharmacol. 1992; 2: 241-243.
7. Sherman AD, Hegwood TS, Baruah S, Waziri R. Deficient NMDA mediated glutamate release from synaptosomes of schizophrenics. Biol. Psychiatry 1991; 20: 1191-1198.
8. Allen RM, Young SJ. Phencyclidine induced psychosis. Am. J. Psychiatry 1978; 135: 1081-1084.
9. Snyder SH. Phencyclidine. Nature 1980; 285: 355-356.
10. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-D-aspartate. Br. J. Pharmacol. 1983; 79: 565-575.
11. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991; 148: 1301-1308.
12. 3H] kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci. Lett. 1983; 40: 245-250.
13. Toru M, Watanabe S, Shibuya H et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of schizophrenic patients. Acta Psychiatr. Scand. 1988; 78: 121-137.
14. Deakin JFW, Slater P, Simpson MD et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 1989; 52: 1781-1786.
15. Kerwin RW, Patel S, Meldrum BS, Czudek C, Reynolds G. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet 1988; 1: 583-584.
16. 3H] Amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to human cerebral cortical membrane: Minimal changes in postmortem brains of chronic schizophrenics. J. Neurochem. 1992; 59: 829-837.
17. 3H]AMPA binding in postmortem human brain from psychotic subjects and controls: Increases in caudate nucleus associated with suicide. Exp. Neurol. 1993; 121: 48-56.
18. Kerwin R, Patel S, Meldrum BS. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 1990; 39: 25-32.
19. 3H] MK-801 binding sites in postmortem brain regions of schizophrenic patients. J. Neur. Transm. 1989; 77: 231-236.
20. Simpson MDC, Slater P, Royston MC, Deakin JFW. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr. Res. 1991; 6: 41-48.
21. Ishimaru M, Kurumaji A, Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: Evidence for glutamate hypothesis. Biol. Psychiatry 1994; 35: 84-95.
22. Ulas J, Managhan DT, Cotman CW. Plastic response of hippocampal excitatory amino acid receptors to deafferentation and reinnervation. Neuroscience 1990; 34: 9-17.
23. Ulas J, Managhan DT, Cotman CW. Kainate receptors in the rat hippocampus: A distribution and time course of changes in response to unilateral lesions of the entorhinal cortex. J. Neurosci. 1990; 10: 2352-2362.
24. Seeman P. Brain dopamine receptors. Pharmacol. Rev. 1980; 32: 229-313.
25. Seiden LS, Sabol KE. Amphetamine: Effects on catecholamine systems and behavior. Ann. Rev. Pharmacol. Toxicol. 1993; 32: 639-677.
26. Itokawa M, Arinami T, Futamura N, Hamaguchi H, Toru M. Astructural polymorphism of human dopamine D2 receptor, D2 (Ser311-Cys). Biochem. Biophys. Res. Communication 1993; 196: 1369-1975.
27. Arinami T, Itokawa M, Enguchi H et al. Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 1994; 343: 703-704.
28. Itokawa M, Toru M, Ito K et al. Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells. Mol. Pharmacol. 1996; 49: 560-566.